Posted by Michael Wonder on 10 Oct 2024
FDA grants fast track designation for biomarker guided DB104 (liafensine) in patients with treatment resistant depression
9 October 2024 - Denovo Biopharma today announced that the US FDA has granted fast track designation for DB104 (liafensine) being developed for treating patients with treatment resistant depression.
Liafensine is a first in class triple re-uptake inhibitor targeting transporters for serotonin, norepinephrine, and dopamine.
